Core Viewpoint - The pharmaceutical industry in China is poised for significant growth due to the potential of the consumer market and the upgrade in health consumption, with technology-driven transformation being crucial for building new productivity and core competitiveness [1][3]. Group 1: Market Potential and Policy Support - China possesses the world's most promising consumer market, which will expand further as health consumption upgrades [1]. - Continuous release of policy benefits will lead to a brighter future for the private economy, with stable and long-term policy support [3]. Group 2: Company Strategy and Commitment - The company, Jiuzhoutong, focuses on serving grassroots rural and remote areas, demonstrating a willingness and capability to address the challenges of these markets [3]. - Jiuzhoutong has established over 400 modern logistics centers nationwide and employs around 5,000 to 6,000 delivery personnel to enhance service in underserved regions [3]. - The company is committed to long-term investment in grassroots services and digitalization, with annual investments amounting to hundreds of millions [4]. Group 3: Long-term Vision and Social Responsibility - The company acknowledges that short-term returns from significant investments may not be immediately visible, but it remains dedicated to its mission [4]. - Meeting the medical service needs of grassroots citizens is seen as both a driving force for the company's development and a social responsibility [4].

"在我看来，'大有可为'昭示着时代赋予的广阔机遇，'正当其时'则呼唤民营企业扛起历史责任。"刘长 云表示，当前国家对民营经济的支持从顶层设计到落地执行，力度空前，而且宏观调控政策因势调整， 政策力度不断加码。此外，中国拥有全球最具潜力的消费市场。仅医药健康领域，市场规模已近5万亿 元，并随着健康消费升级持续扩容。而数字化、人工智能等新质生产力正在重塑医药行业格局。这种以 技术为核心的转型，正是民营企业把握"大有可为"机遇、锻造核心竞争力的关键所在。 作为新时代的民营企业家，刘长云认为优秀建设者应具备三点核心特质。首先，政治立场坚定，厚植家 国情怀。始终拥护党的领导，将企业发展融入国家战略，将社会责任内化为企业文化基因。其次，坚持 内涵式增长，追求高质量发展。当前国家力推新质生产力，实业企业更要以"质"为刃，用创新取代粗 放。最后，企业守法经营，企业家诚信自律。守法经营是民营企业的生命线，诚信自律是发展的通行 证，这不仅是对民营企业家的基本要求，更是企业核心竞争力的体现。 在弘扬企业家精神方面，刘长云表示，应以创新引擎锻造新质生产力，扛起科技自立自强使命，"这是 新时代建设者的硬核担当"。同时，践行共同富裕，筑 ...

Core Viewpoint - The meeting highlighted the importance of private enterprises in promoting the spirit of entrepreneurship and contributing to the construction of socialism with Chinese characteristics, particularly in the healthcare sector focusing on rural medical services [1]. Group 1: Company Insights - Liu Changyun, Chairman of Jiuzhoutong Pharmaceutical Group, emphasizes the need for a sense of responsibility and national sentiment in serving grassroots medical needs, particularly in remote areas where access to healthcare is limited [3]. - The company faces challenges such as high delivery costs, low profit margins, and difficulties in sourcing less commonly used medications that are critical for rural healthcare [4]. - Jiuzhoutong has established over 400 modern logistics centers nationwide and employs around 5,000 delivery personnel to enhance service efficiency in remote areas [4]. Group 2: Industry Trends - The company is committed to long-term investments in grassroots healthcare services and digitalization, with annual expenditures amounting to hundreds of millions, despite short-term returns being less apparent [5]. - The ongoing "Healthy China" strategy is expected to improve the grassroots healthcare market, which is seen as both a business opportunity and a social responsibility for the company [5].

Group 1 - The meeting highlighted the importance of promoting entrepreneurial spirit among private enterprises in China, emphasizing their role in the development of socialism with Chinese characteristics [3][53]. - Wang Xingxing, CEO of Yushu Technology, expressed confidence in humanoid robots becoming mainstream technology in the next 3 to 5 years, with significant growth in application scenarios across various sectors [1][45]. - Liu Baiqi, founder of Xinghe Power, discussed the development of the reusable rocket Zhi Shen Xing 2, which has a basic payload capacity of 20 tons and can be adapted for various space missions, aiming to reduce launch costs significantly [2][33]. Group 2 - The private sector is seen as having a bright future, with supportive policies and a conducive environment for innovation and development, as noted by various entrepreneurs during the meeting [20][26]. - The commercial space industry is rapidly growing, with Xinghe Power completing 19 successful rocket launches, establishing itself as a leading private rocket company in China [13][24]. - The meeting underscored the need for traditional manufacturing sectors to embrace green and low-carbon development, digital transformation, and innovation to achieve high-quality growth [50][52]. Group 3 - Yushu Technology has achieved significant technological advancements in high-performance quadruped and humanoid robots, aiming to promote their application in various fields [5][45]. - The meeting featured discussions on the challenges and opportunities faced by industries, including the need for innovation and adaptation to changing market demands [37][38]. - The entrepreneurs emphasized the importance of social responsibility and the integration of corporate development with national strategies, reflecting a commitment to contributing to society [41][48].

来源：国务院新闻办公室网站 据国新网7月14日消息，国务院新闻办公室将于2025年7月15日（星期二）下午3时举行"新征程上的奋斗者"中外记者 见面会，请民营企业家代表（名单附后）围绕"弘扬企业家精神，坚定做优秀中国特色社会主义事业建设者"与中外记者 见面交流。 官方公布的出席人员名单包括：杭州宇树科技股份有限公司创始人兼首席执行官王兴兴，山东魏桥创业集团有限公司董 事长张波，内蒙古鄂尔多斯投资控股集团有限公司总裁王臻，北京星河动力航天科技股份有限公司创始人、董事长刘百 奇，九州通医药集团股份有限公司董事长刘长云。 1秒钟，20%涨停！ ...

据国新网7月14日消息，国务院新闻办公室将于2025年7月15日（星期二）下午3时举行"新征程 上的奋斗者"中外记者见面会，请民营企业家代表围绕"弘扬企业家精神，坚定做优秀中国特色 社会主义事业建设者"与中外记者见面交流。 官方公布的出席人员名单包括： 杭州宇树科技股份有限公司创始人兼首席执行官王兴兴，山 东魏桥创业集团有限公司董事长张波，内蒙古鄂尔多斯投资控股集团有限公司总裁王臻，北京 星河动力航天科技股份有限公司创始人、董事长刘百奇以及九州通医药集团股份有限公司董事 长刘长云。 出席人员名单 王兴兴 杭州宇树科技股份有限公司创始人兼首席执行官 张 波 山东魏桥创业集团有限公司董事长 王 臻 内蒙古鄂尔多斯投资控股集团有限公司总裁 刘百奇 北京星河动力航天科技股份有限公司创始人、董事长 刘长云 九州通医药集团股份有限公司董事长 ...

智通财经7月14日电，据国新网7月14日消息，国务院新闻办公室将于2025年7月15日（星期二）下午3时 举行"新征程上的奋斗者"中外记者见面会，请民营企业家代表围绕"弘扬企业家精神，坚定做优秀中国 特色社会主义事业建设者"与中外记者见面交流。 官方公布的出席人员名单包括：杭州宇树科技股份有限公司创始人兼首席执行官王兴兴，山东魏桥创业 集团有限公司董事长张波，内蒙古鄂尔多斯投资控股集团有限公司总裁王臻，北京星河动力航天科技股 份有限公司创始人、董事长刘百奇以及九州通医药集团股份有限公司董事长刘长云。 宇树科技创始人王兴兴等民营企业家将亮相中外记者见面会 ...

Group 1 - The establishment of Xizang Jiuzhoutong Suodang Technology Co., Ltd. in Shannan City marks the first Wuhan pharmaceutical enterprise in the region, aiming to enhance smart healthcare and promote local pharmaceutical products nationwide [1] - The company is a joint venture between Jiuzhoutong Pharmaceutical Group and Naidong District Suodang Investment Co., Ltd., focusing on medical device sales and information technology, which are core business areas of Jiuzhoutong [1] - Jiuzhoutong Pharmaceutical Group plans to achieve sales of 37.8 billion yuan in medical devices by 2024 and has established a lean management service for medical supplies with over 100 top-tier hospitals across the country [1] Group 2 - The creation of the company reflects a strategic layout for the enterprise and represents an upgrade in the aid model from basic healthcare to technology services, driven by the 11th aid team from Wuhan [2] - The long-term cooperation and cultural exchange between Wuhan and Naidong have fostered deep ties and mutual support, resulting in significant achievements over 31 years of assistance [2]

Core Viewpoint - The company is transforming its development momentum through the "Three New and Two Transformations" strategy, focusing on digital transformation, new retail, and new medical services to become the most professional health service provider in China and achieve its goal of becoming a century-old enterprise [1][7]. Digital Empowerment - The company has evolved from a grassroots pharmaceutical wholesaler to a technology-driven comprehensive service provider in the pharmaceutical industry, with a clear strategic path and implementation results in its digital transformation [1][2]. - The digital transformation includes collaboration across business, management, and logistics, with a focus on reducing costs and increasing efficiency [2][3]. - The company has achieved a significant reduction in logistics errors, with an error rate controlled at one in a million, enhancing both efficiency and quality [2]. Strategic Focus - The "Three New" strategy addresses the long-standing "two disconnections" in the industry by enhancing control over upstream products and establishing a new retail network for downstream channels [2][5]. - The company aims for new product-related sales to account for 20% of total revenue and 50% of gross profit in the next three years [3][5]. Medical Aesthetics Business - The company is accelerating its layout in the medical aesthetics sector, which has shown rapid growth, increasing from several million to several billion in scale [5][6]. - The medical aesthetics market is seen as a key profit growth point, driven by the aging population and rising consumer demand for beauty services [5][6]. Talent Strategy - The company has shifted its talent acquisition strategy, significantly increasing the recruitment of external senior talent to meet the demands of its strategic transformation [6][7]. - In 2023, the company introduced a "Three Transformations Talent Strategy," aiming to recruit over 300 senior talents annually [6]. Financial Performance - The company's sales revenue has grown from 21.185 billion in 2010 to 151.81 billion in 2024, with a compound annual growth rate of 15.10% [6]. - The net profit attributable to the parent company increased from 360 million in 2010 to 2.507 billion in 2024, with a compound annual growth rate of 14.88% [6].

Core Insights - The medical beauty sector is witnessing an influx of new players, with pharmaceutical companies and beauty brands aggressively entering the market, indicating a significant industry transformation driven by consumer demand and technological advancements [2][3][5]. Group 1: Market Dynamics - Major pharmaceutical companies, including China National Pharmaceutical Group, Shanghai Pharmaceuticals, and China Resources Pharmaceutical, are entering the medical beauty market, establishing comprehensive collaborations in research, production, and distribution [3][5]. - The medical beauty market in China is projected to reach a scale of 638.2 billion yuan by 2030, with a compound annual growth rate (CAGR) of 14.5% from 2021 to 2030 [6][7]. Group 2: Company Strategies - Jiuzhoutong, a leading pharmaceutical distributor, has successfully expanded its medical beauty segment, reporting a sales revenue of 851 million yuan in 2024, a significant increase of 120.47% year-on-year [7]. - Beauty companies are increasingly focusing on "medical device" products, which require regulatory approval and are perceived to have higher consumer willingness to pay, as evidenced by the introduction of medical dressings and other related products [8][10]. Group 3: Competitive Landscape - The competition in the beauty sector is intensifying, with companies exploring various strategies such as mergers and acquisitions, technological extensions, brand crossovers, channel integration, and collaborative research with medical institutions [10][11]. - The entry of beauty brands into the medical beauty space is seen as a strategic move to capture new growth opportunities amid fierce competition in traditional beauty products [10][11].